IP Library Granted Patent US 9,090,708
Granted Patent B2
US 9,090,708 · App. 13/316,791 · Granted Jul 28, 2015

Porcine CTLA-4 for xenograft-specific immunosuppression

Inventors: Robert Ian Lechler (London, GB); Anthony Dorling (London, GB)
Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED
C07K14/70596A01K67/0275A61K39/001C07K14/70521C07K14/70532C07K16/2818A01K2217/05A61K38/00A61K48/00A61K2039/5154A61K2039/5156C07K2317/622C07K2319/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,708
App. No.
13/316,791
Granted
Jul 28, 2015
Kind
B2
Abstract

The invention provides methods for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 (the B7/CD28 interaction) prevent the activation of xenoreactive T-cells in the recipient. In a first aspect, co-stimulation is prevented by administration to the organ recipient of a soluble form of CTLA-4 from the xenogeneic donor organism. In a second aspect, co-stimulation is antagonized by expressing a ligand for CTLA-4 on the xenogeneic donor cells. In a third aspect, co-stimulation is prevented by expressing recipient organism MHC class II on the surface of the cells of the xenogeneic donor organ.

Claims (14)

1. A non-human cell transformed with a vector which expresses a nucleic acid which encodes a porcine CTLA4 protein or fragment thereof.

2. The cell according to claim 1 wherein the CTLA4 protein comprises the extracellular domain of porcine CTLA-4.

3. The cell according to claim 1 , wherein the CTLA-4 protein comprises the extracellular domain of porcine CTLA4 fused to a human Cγ1 sequence.

4. The cell of claim 1 wherein the nucleic acid comprises SEQ ID NO: 2.

5. The cell according to claim 1 wherein the CTLA4 protein is fused to the constant domain of an immunoglobulin.

6. The cell of claim 3 , wherein the immunoglobulin gamma comprises a constant region of the human Cγ1 subtype.

7. The cell of claim 5 , wherein a linker connects the porcine CTLA-4 to the immunoglobulin and the linker comprises the amino acid sequence GGSGGAA (SEQ ID NO: 28).

8. The cell of claim 1 wherein the CTLA-4 protein is fused to an immunoglobulin.

9. The cell of claim 8 , wherein the immunoglobulin is a human immunoglobulin.

10. The cell of claim 8 , wherein the human immunoglobulin is immunoglobulin gamma (IgG).

11. The cell of claim 10 , wherein the immunoglobulin gamma comprises a constant region of the human Cγ1 subtype.

12. The cell of claim 8 , wherein a linker connects the porcine CTLA-4 to the immunoglobulin.

13. The cell of claim 12 , wherein the linker comprises the amino acid sequence GGSGGAA (SEQ ID NO: 28).

14. The cell of claim 2 wherein the extracellular domain of the porcine CTLA-4 protein comprises amino acid sequence numbers 38-161 of SEQ ID NO: 1.

Assignments (1)
CHANGE OF NAME Recorded Jun 26, 2014
From: IMPERIAL COLLEGE INNOVATIONS LIMITED
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 033184/0199 →
Priority Claims (1)
GB 9809280.2 · Apr 30, 1998 · national
Continuity (3)
Continuation 12231608 · Sep 4, 2008
Continuation 09674462
Related Publication 20130078266A1 · Mar 28, 2013